DED Magnified: A Real-World Case Library - Case 3

Activity Description and Purpose

Most patients with cataracts also have dry eye disease (DED), and optimization of the ocular surface prior to cataract surgery is crucial for successful surgical outcomes. More recent additions to an already large treatment armamentarium available for DED can make it challenging to select the treatment(s) that will successfully manage a patient’s DED quickly so that surgery can proceed. In this third case of the DED Magnified: A Real-World Case Library series, Sheri Rowan, MD, walks through her effective and successful treatment of a patient with DED and severe bilateral cataracts.

Target Audience

This educational activity is intended for ophthalmologists and optometrists.

Learning Objectives

After completing this activity, participants will be better able to:
  • Review causative factors of dry eye disease
  • Design evidence-based treatment plans for persons with dry eye disease

You may also be interested in

DED Magnified: A Real-World Case Library - Case 1
In this first case of the series, Dr Walter O. Whitley describes the diagnosis and treatment of a patient with dry eye disease due to meibomian gland dysfunction, along with the latest clinical evidence on new treatments for dry eye disease.
DED Magnified: A Real-World Case Library - Case 2
In this second case of the DED Magnified: A Real-World Case Library series, Dr. Marc R. Bloomenstein identifies the tale-tell signs and symptoms of a case of evaporative dry eye disease and the optimization of treatment for the patient.
Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 COPE
  • 0.75 Participation
Course opens: 
07/12/2024
Course expires: 
07/31/2025

Faculty

Sheri Rowen, MD
NVISION Eye Center
Newport Beach, California

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Sheri Rowen, MD, is a consultant for AbbVie Inc, Atia Vision, Inc, Azura Ophthalmics, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, Inc, OcuTerra Therapeutics, Orasis Pharmaceuticals, and RxSIGHT; is on the speakers bureau for AceVision, Atia Vision, Inc, Bausch & Lomb Incorporated, Orasis Pharmaceuticals, RxSIGHT, and ScienceBased Health; is an advisory board member of Centricity Vision, Inc, Thea Pharmaceuticals Limited, and Visus Therapeutics; and has stock options that have not been exercised in Orasis Pharmaceuticals.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

 MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 COPE approved for 0.75 CE credit for optometrists.
COPE Course ID: 92246-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease

Administrator:

This activity, COPE Activity Number 128803, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.

The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.

This CME/CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 302.2c

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 COPE
  • 0.75 Participation
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CME/CE information for this activity.